If you're going to point that out you should at least ask your chatbot buddy (not to be confused with your Peptide Buddy) for the history on it being studied in men, what concerns arose, if that related to dosing method imprecision (e.g. nasal VS injection) or is likely to represent a broader risk, and who specifically should heed that concern. I think that all would be valuable history for those researchers out there who may be pondering their options (and perhaps if it might be wiser to wait until other research they're already doing "pays off" first).Calm Logic said:As a reminder, PT-141 is only FDA approved for women and for only some women at that (as Vyleesi for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women).
